Advertisement

Pharmacodynamics of 5-Fluorouracil and Leucovorin

  • Bengt G. Gustaysson
  • Göran Carlsson
  • Roland Frösing
  • C. Paul Spears
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 131)

Abstract

Fluoropyrimidine therapy is a corner-stone of chemotherapeutic management of metastatic cancer. Although only about 15% of patients respond to initial single-agent FUra therapy, a greater number may have disease stabilization with comparatively mild toxicity1,2. Fifteen years ago, we reported that continuous intraportal infusion of Fyra in a significant prolonged survival compared to historical controls3. Since then, significant discoveries of the mechanisms of action of FUra and attempts at rational approaches in its application have been made.

Keywords

Folinic Acid Group FUra Murine Colon Adenocarcinoma Fluoropyrimidine Therapy Chemotherapeutic Management 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    B. Gustaysson and L. O. Hafström, Adjuvant and palliative treatment of colo-rectal cancer with fluorinated pyrimidines - a pharmacological and clinical review, Acta Chir Scand Suppl 504 (1981).Google Scholar
  2. 2.
    F. Ansfield, J. Klotz, T. Nealon, G. Ramirez, J. Minton, G. Hill, W. Wilson, H. Davis, and G. Cornell, A phase III study comparing the clinical utility of four regimens of 5-fluoruracil, Cancer 39: 34 (1977).PubMedCrossRefGoogle Scholar
  3. 3.
    O. Almersjö, L. O. Hafström, and B. Gustaysson, Results of regional portal infusion of 5-fluorouracil to patients with primary and secondary liver cancer, Acta Chir Gyn Fenn 65: 27 (1976).Google Scholar
  4. 4.
    C. P. Spears, B. G. Gustaysson, M. S. Mitchell, D. Spicer, M. Berne, L. Bernstein, and P. V. Danenberg, Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil, Cancer Res 44: 4144 (1984).PubMedGoogle Scholar
  5. 5.
    C. P. Spears, B. G. Gustaysson, and R. Frösing, Folinic acid modulation of fluorouracil: kinetics of bolus administration, Invest New Drugs 6: in press (1988).Google Scholar
  6. 6.
    C. P. Spears, A. H. Shahinian, R. G. Moran, C. Heidelberger, and T. H. Corbett, In vivo kinetics of thymidylate synthetase inhibition in 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas, Cancer Res 42:450 (1982).PubMedGoogle Scholar
  7. 7.
    C. P. Spears and B. G. Gustaysson, Methods for thymidylate synthase pharmacodynamies: serial biopsy, free and total TS, FdUMP and dUMP, and H4PteGlu and CH -H PteGlu assays, in: “The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy”, Y. Rustum and J. McGuire eds., Plenum Publ Corp, N.Y. (1988).Google Scholar
  8. 8.
    G. Carlsson, L. Hafström, and B. Gullberg, Estimation of liver tumor volume using different formulas. An experimental study in rats, J Cancer Res Clin Oncol 105: 20 (1983).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Bengt G. Gustaysson
    • 1
    • 2
  • Göran Carlsson
    • 1
    • 2
  • Roland Frösing
    • 1
    • 2
  • C. Paul Spears
    • 1
    • 2
  1. 1.Östra sjukhusetThe University of GothenburgSweden
  2. 2.Comprehensive Cancer CenterThe University of Southern CaliforniaLos AngelesUSA

Personalised recommendations